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ABSTRACT 
Background: Changing etiologic patterns and the growing problem of antimicrobial re- 
sistance, particularly an increase in macrolide-resistant pneumococcal bacteremia, are 
causing physicians to adopt new approaches to the treatment of community-acquired 
pneumonia (CAP). 
Objective: The relative efficacy and tolerability of levofloxacin monotherapy and az- 
ithromycin and ceftriaxone combination therapy were assessed in hospitalized adults with 
moderate to severe CAP. 
Methods: This Phase IV, multicenter, open-label, randomized trial compared 2 treat- 
ment regimens: (1) levofloxacin 500 mg PO or IV q24h, and (2) azithromycin 500 mg IV 
q24h for ~2 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional tran- 
sition to azithromycin 500 mg PO q24h at the investigator’s discretion. The total duration 
of therapy was to be a minimum of 10 days in both treatment groups. Ceftriaxone was 
included in the initial azithromycin regimen to ensure coverage against pneumococcal 
bacteremia. 
Results: Of 236 patients in the intent-to-treat population, completion or withdrawal in- 
formation was available for 110 patients in the levofloxacin group and 114 in the azith- 
romycin group. Baseline demographic and disease characteristics were comparable be- 
tween groups. At the end of treatment, the clinical success rate (cured + improved) in 
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clinically evaluable patients was 94.1% in 
the levofloxacin group and 92.3% in the 
azithromycin group. The respective post- 
therapy microbiologic eradication rates 
were 89.5% and 92.3%. Levofloxacin was 
as well tolerated as azithromycin, with an 
incidence of drug-related adverse events 
(AEs) for all body systems of 5.3% and 
9.3%, respectively. One patient receiving 
levofloxacin had a serious drug-related 
AE, compared with 7 patients receiving 
azithromycin. 
Conclusions: In this study in hospital- 
ized patients with moderate to severe CAP, 
levofloxacin monotherapy was at least as 
effective as a combination regimen of az- 
ithromycin and ceftriaxone in providing 
coverage against the current causative 
pathogens in CAP. In addition, levo- 
floxacin was as well tolerated as the com- 
bination of azithromycin and ceftriaxone. 
Key words: levofloxacin, community- 
acquired pneumonia, fluoroquinolones, 
clinical trial. (Clin Thu. 2002;24: 1292- 
1308) 
INTRODUCTION 
Despite the availability of effective an- 
timicrobial agents, community-acquired 
pneumonia (CAP) remains a potentially 
life-threatening infection of the lower res- 
piratory tract. The overall mortality rate 
among patients hospitalized with CAP 
ranges from 5% to 25%, whereas the mor- 
tality rate in those with severe illness re- 
quiring treatment in the intensive care unit 
ranges from 20% to 50%.lJ Streptococ- 
cus pneumoniae is the most common eti- 
ologic agent in hospitalized patients with 
CAP, particularly those with severe dis- 
ease. 3,4 Pneumococcal bacteremia is a ma- 
jor complication in hospitalized patients 
with CAP, with an attributable mortality 
rate ranging from 20% to 4 1% .5 The mor- 
tality rate in patients with severe CAP 
who are bacteremic is -3 times that in pa- 
tients with severe CAP who have nega- 
tive blood cultures6 
The significant risk of bacteremia in 
patients with moderate to severe CAP sup- 
ports selection of an antibiotic regimen 
for initial in-hospital therapy that is active 
against the main causative pathogens 
while achieving high drug concentrations 
in plasma and lung tissue. Results of a 
retrospective investigation in patients with 
severe bacteremic pneumococcal pneu- 
monia suggest that monotherapy may pro- 
duce suboptimal outcomes in this popula- 
tion.7 However, a retrospective review of 
98 cases of CAP-associated pneumococ- 
cal bacteremia from prospective, random- 
ized, controlled clinical trials demon- 
strated a clinical success rate of 96.9% 
and a microbiologic success rate of 95.9% 
with levofloxacin 500 mg/d.8 In addition, 
the Infectious Diseases Society of Amer- 
ica (IDSA) recommends use of doxycy- 
cline, macrolides, or fluoroquinolones for 
the empiric treatment of most outpatient 
cases of CAP and either a fluoroquinolone 
alone or a beta-lactatieta-lactamase in- 
hibitor or extended-spectrum cephalo- 
sporin combined with a macrolide for 
most hospitalized patients with CAP in a 
general medical ward? 
This study compares the efficacy and 
tolerability of 2 regimens -monotherapy 
with levofloxacin and combination ther- 
apy with azithromycin and ceftriaxone- 
that meet IDSA criteria for the treatment 
of CAP. Both are used for empiric treat- 
ment of moderate to severe CAP, although 
recently there has been increased concern 
about the association of macrolides 
with macrolide-resistant pneumococcal 
bacteremia.lO,ll 
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PATIENTS AND METHODS 
Study Design 
This was a Phase IV, multicenter, open- 
label, randomized trial comparing the ef- 
ficacy and tolerability of levofloxacin 
monotherapy and the combination of az- 
ithromycin and ceftriaxone in hospitalized 
patients with moderate to severe CAP. 
Znclusion and Exclusion Criteria 
Patients aged 218 years were eligible 
for the study if they had a diagnosis of 
moderate to severe pneumonia acquired 
in the community or in a nursing home. 
The diagnostic criteria included (1) char- 
acteristic clinical signs, including ~1 of 
the following-fever (oral temperature 
>38”C), hypothermia (oral temperature 
<35.5”C), leukocytosis (>lO,OOO white 
blood cells/mm3), or bands >lO%; (2) ra- 
diologic evidence of pneumonia (an acute 
infiltrate consistent with pneumonia on 
chest radiography); (3) collection of a mu- 
copurulent sputum specimen for culture 
and Gram’s staining within 24 hours be- 
fore study drug administration; and (4) a 
Fine risk score12 of 71 to 130 (indicative 
of moderate to severe disease and associ- 
ated need for hospitalization) at study in- 
clusion. Patients who had received previ- 
ous antimicrobial therapy for any infection 
were allowed to participate if the total du- 
ration of previous therapy was ~24 hours 
or the patient had received >72 hours of 
therapy but was classified as a treatment 
failure. 
Women of childbearing potential were 
required to have had normal menstrual 
flow in the month before study entry, to 
have a negative result on serum pregnancy 
testing (human chorionic gonadotropin l3 
subunit) immediately before study entry 
or a negative urine pregnancy test (sensi- 
tive to 50 mIU/mL) if serum pregnancy 
testing would delay treatment; and to have 
been using hormonal contraception for 2 1 
month before study entry, to have an in- 
trauterine device, or to consent to using a 
spermicide/barrier method of contracep- 
tion. Whichever method of contraception 
was in use at the time of study entry was 
to be continued throughout the study. 
Women who had been postmenopausal for 
81 year or had been rendered surgically 
menopausal were also eligible. 
Patients were excluded from study par- 
ticipation if they had an infection caused 
by a pathogen known or suspected to be 
resistant to any of the study drugs before 
their admission to the study or if they had 
experienced an allergic reaction or seri- 
ous adverse reaction to levofloxacin, 
azithromycin, ceftriaxone, or any other 
member of the quinolone, macrolide, or 
beta-lactam class of antimicrobial agents. 
Patients were also ineligible if they had 
been hospitalized within 2 weeks before 
study entry (or within 1 month before 
study entry if antimicrobial therapy had 
been administered during this time), or if 
their life expectancy was ~72 hours. 
Other exclusion criteria included creat- 
inine clearance <20 mL/min (when only 
serum creatinine data were available, the 
Cockcroft-Gault equation was used to cal- 
culate creatinine clearance); empyema or 
the presence of pleural fluid requiring an 
indwelling chest tube; pneumonia due to 
aspiration of gastric contents; HIV infec- 
tion, with a CD4 cell count <200/cm3; 
presence of any seizure disorder or a psy- 
chiatric condition requiring chronic use of 
tranquilizers; or presence of any disease 
or disorder that could interfere with eval- 
uation of the study treatments. Patients 
who had received any experimental drug 
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within 30 days before study entry were 
also excluded. 
All patients, or their legally authorized 
representatives, provided written in- 
formed consent. 
Study Treatments 
Randomization was conducted accord- 
ing to a computer-generated schedule pre- 
pared by Ortho-McNeil before initiation 
of the study. Patients were randomized in 
a 1: 1 ratio to 1 of 2 treatment groups: levo- 
floxacin 500 mg PO or IV q24h, or azith- 
romycin 500 mg IV q24h for 22 days plus 
ceftriaxone 1 g IV q24h for 2 days, fol- 
lowed by an optional transition to az- 
ithromycin 500 mg PO q24h at the in- 
vestigator’s discretion. Ceftriaxone was 
included in the initial azithromycin regi- 
men to ensure coverage against pneumo- 
coccal bacteremia. The first dose of study 
drug was administered as soon as admis- 
sion procedures were completed and could 
be given in the emergency department. 
Thereafter, all doses were administered in 
the morning. Oral levofloxacin therapy 
could be started at the time of study entry 
or as soon as oral medication could be 
tolerated. The duration of therapy was to 
be a total of 10 days in both treatment 
groups. 
Levofloxacin could be administered 
without regard to meals, whereas oral az- 
ithromycin was taken 21 hour before or 
>2 hours after a meal. In the levofloxacin 
group, patients with a calculated creati- 
nine clearance of 20 to 49 mL/min re- 
ceived an initial loading dose of levo- 
floxacin 500 mg, followed by 250 mg 
q24h. Patients with hepatic or renal im- 
pairment were administered azithromycin 
and ceftriaxone with caution, as specified 
in the respective package inserts. 
The use of systemic corticosteroids was 
contraindicated during the study, unless 
such therapy was already being received 
for an unrelated medical condition. Pa- 
tients requiring antacid therapy were 
strongly advised to use compounds con- 
taining calcium carbonate rather than 
magnesium-aluminum hydroxide or su- 
cralfate. If either of the latter was used, it 
was to be taken >2 hours after study drug 
administration. Theophylline levels were 
closely monitored as clinically appropri- 
ate in both treatment groups, with dose 
adjustment as necessary. Because concur- 
rent use of macrolides or some quinolones 
and warfarin or its derivatives has been 
associated with increased anticoagulant 
effects in clinical practice,13 the prothrom- 
bin time was closely monitored as clini- 
cally indicated in patients receiving war- 
farin or its derivatives. Given reports of 
drug interactions between macrolides and 
digoxin, ergotamine/dihydroergotamine, 
triazolam, carbamazepine, terfenadine, 
cyclosporine, hexobarbital, and pheny- 
toin,14 patients receiving any of these 
drugs in combination with azithromy- 
tin were monitored closely as clinically 
indicated. 
Study Evaluations 
Patients were evaluated at the initial 
(admission) visit, at which time a medical 
history was obtained and a physical ex- 
amination was performed. The severity of 
pneumonia was assessed in terms of the 
Fine risk score,‘* and posteroanterior and 
lateral chest radiographs were obtained. 
All patients were required to have a mu- 
copurulent sputum specimen, which was 
sent for Gram’s staining and culture. A 
urine specimen was obtained for preg- 
nancy testing, if applicable. Blood sam- 
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ples were obtained for culture, serum preg- 
nancy testing, complete blood count 
with differential, and measurement of ar- 
terial pH, blood urea nitrogen, sodium, 
glucose, and arterial partial pressure of 
oxygen. Any concomitant therapies were 
recorded. Treatment with study drug was 
then initiated. 
Patients’ clinical status was evaluated 
-72 hours after the start of treatment (days 
3-5). Those whose condition had not sta- 
bilized or whose clinical signs/symptoms 
had worsened after 72 hours were with- 
drawn from the study and were consid- 
ered treatment failures. These patients 
were switched to an appropriate alter- 
native therapy. Those whose condition 
had stabilized but was not yet improved 
could continue in the study at the inves- 
tigator’s discretion. Patients whose ad- 
mission organism was determined to be 
resistant to study drug could also remain 
in the study at the investigator’s discre- 
tion, provided they were clinically stable 
or improving. 
General, nondirected questioning was 
used to elicit adverse events (AEs) occur- 
ring during treatment. Blinding to treat- 
ment assignment was not possible because 
of the investigator’s freedom to change 
the route of administration or discontinue 
ceftriaxone .
Between days 2 and 7 after the comple- 
tion of therapy (or at early withdrawal), a 
physical examination was performed, in- 
cluding recording of vital signs. Clinical 
signs and symptoms were evaluated, and 
the patient’s clinical response was assessed. 
Posteroanterior and lateral chest radio- 
graphs were obtained, as was a sputum 
sample for Gram’s staining and culture, if 
available. If the admission culture had been 
positive or the patient was considered a 
clinical failure, a blood sample was drawn 
for routine culture. Patients were ques- 
tioned about any AEs that had occurred 
during the study. 
Ef$cacy and Safety Assessments 
The primary efficacy variable was the 
clinical response at the posttherapy (or 
early-withdrawal) assessment in clinically 
evaluable patients (see Statistical Analy- 
sis section for definitions of study popu- 
lations). Secondary efficacy variables in- 
cluded the posttherapy microbiologic 
response by infection; the posttherapy mi- 
crobiologic response for each pathogen 
isolated from an admission sputum cul- 
ture; and the posttherapy microbiologic 
response for blood pathogens isolated at 
admission. 
Clinical Ejkacy 
Clinical efficacy was assessed by com- 
paring the signs, symptoms, and radiologic 
findings from the posttherapy (or early- 
withdrawal) evaluation with those from 
the admission evaluation. The following 
definitions were used to categorize the 
clinical response: clinical cure-resolu- 
tion of pretreatment clinical signs and 
symptoms (radiographic resolution not re- 
quired) and no need for additional antimi- 
crobial therapy; improved- significant im- 
provement in clinical findings, but clinical 
evidence of resolution incomplete during 
therapy or at follow-up evaluation in a pa- 
tient not requiring additional antimicrobial 
therapy; failure-incomplete response or 
no apparent response to therapy, and need 
for additional antimicrobial therapy; and 
unevaluable-clinical evaluation of cure, 
improvement, or failure not possible be- 
cause of inadequate follow-up data, use of 
concomitant antimicrobial therapy, or pro- 
tocol violation. 
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Microbiologic Eficacy 
Microbiologic response was assessed 
by comparing the results of culture from 
the posttherapy (or early-withdrawal) 
evaluation with those from the admission 
evaluation. Based on the posttherapy (or 
early-withdrawal) culture results, each ad- 
mission pathogen was assigned to 1 of the 
following categories of microbiologic re- 
sponse: eradicated-negative results on 
culture in the absence of additional 
antimicrobial therapy; presumed eradi- 
cated-no respiratory specimen available 
for culture and a clinical response of clin- 
ical cure or improved in the absence of 
additional antimicrobial therapy; per- 
sisted-positive posttherapy culture; pre- 
sumed persisted- in patients with a clin- 
ical response of clinical failure, no culture 
or a negative test-of-cure culture while re- 
ceiving additional antimicrobial therapy; 
and unable to evaluate-in patients with 
a clinical response of clinical cure, im- 
proved, or unable to evaluate, no test-of- 
cure culture due to loss to follow-up or 
premature withdrawal, or a negative cul- 
ture or no test-of-cure culture in the pres- 
ence of additional antimicrobial therapy. 
Later reevaluation identified any organ- 
isms that had been susceptible to study 
treatment at admission but subsequently 
acquired resistance. 
At the posttherapy evaluation, each pa- 
tient’s infection was assigned to 1 of the 
following categories of microbiologic re- 
sponse based on the microbiologic re- 
sponse of all pathogens isolated in that 
patient at admission: eradicated/presumed 
eradicated-all pathogens isolated at ad- 
mission were eradicated or presumed to 
have been eradicated; mixed- 2 1 pathogen 
isolated at admission was eradicated or 
presumed to have been eradicated, while 
others persisted or were presumed to have 
persisted; persisted/presumed persisted- 
all pathogens isolated at admission per- 
sisted or were presumed to have persisted; 
and unable to evaluate-a judgment could 
not be made. 
Bacteremia was defined as 1 blood cul- 
ture result positive for a pathogen at ad- 
mission. In patients for whom no blood 
culture was available at the posttherapy 
evaluation, the microbiologic response 
was classified as unknown if the clinical 
response was cured or improved and as 
presumedpersisted if the clinical response 
was failure. Superinfection was defined 
as the emergence or worsening of clinical 
signs and symptoms requiring additional 
antimicrobial therapy when a pathogen 
not isolated at admission was isolated 
from any site through the posttherapy 
evaluation. 
Safety 
Tolerability was assessed based on find- 
ings of the physical examinations and lab- 
oratory tests performed during the study 
and AEs reported by patients. Safety pa- 
rameters were assessed separately for 
oral and parenteral therapy. Treatment- 
emergent AEs were defined as new-onset 
AEs or existing AEs whose severity or 
frequency was exacerbated after adminis- 
tration of study drug, based on the inves- 
tigator ‘s judgment. 
Analysis Plan 
Five populations were identified for the 
purposes of analysis. The intent-to-treat 
population included all randomized pa- 
tients. The modified intent-to-treat popu- 
lation included those patients who had a 
confirmed diagnosis of moderate to se- 
vere CAP and received sl dose of study 
drug. The clinically evaluable population 
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included patients who had clinical signs/ 
symptoms at admission and a chest radio- 
graph consistent with acute pneumonia; 
had a clinical response other than unable 
to evaluate; had received consecutive 
doses of protocol-specified drug on days 
1 through 3 at minimum and ~7 doses 
during the first 10 days (patients who dis- 
continued study treatment as a result of 
clinical failure after 72 hours of consecu- 
tive therapy were considered evaluable); 
had received no concomitant or postther- 
apy treatment with another effective sys- 
temic antibiotic; and had a valid postther- 
apy evaluation. The microbiologically 
evaluable population included patients 
who were evaluable for clinical efficacy; 
had a specimen for culture obtained within 
24 hours before starting study treatment; 
had an admission pathogen recognized as 
a potential cause of CAP; and had a valid 
posttherapy evaluation, including a speci- 
men for culture, if available. The safety 
population included patients who took ~1 
dose of study medication. 
The primary efficacy variable was the 
posttherapy clinical response (cured, im- 
proved, failed, or unable to evaluate) in 
clinically evaluable patients. Clinical suc- 
cess was derived by combining the clinical 
responses cured and improved. Clinical 
success rates and by-patient microbiologic 
eradication rates were analyzed by treat- 
ment group for each population. 
To evaluate whether levofloxacin was 
at least as effective as azithromycin, 
2-sided 95% CIs (normal approxima- 
tion to the binomial with a continuity 
correction) were computed around the 
treatment differences (azithromycin - 
levofloxacin) in posttherapy response 
rates.15 Statistical equivalence (ie, levo- 
floxacin at least as effective as azithro- 
mycin) was considered to be demonstrated 
if the 95% CI crossed zero and the upper 
limit was s15%.16 
Posttherapy microbiologic eradication 
rates were summarized for microbiologi- 
tally evaluable patients in each treatment 
group by pathogen category (gram- 
positive vs gram-negative aerobes); patho- 
gen and infection overall; and pathogen 
within each culture category (respiratory, 
blood, most prevalent pathogens). Two- 
sided 95% CIs were computed around the 
treatment differences (azithromycin - 
levofloxacin) in posttherapy microbiolog- 
ic response rates. In microbiologically 
evaluable patients, a cross-tabulation of 
by-patient microbiologic response versus 
clinical response was performed. Patho- 
gens were classified by those isolated 
from respiratory cultures and those iso- 
lated from blood cultures. In clinically 
evaluable patients, posttherapy clinical re- 
sponse rates by pathogen within each cul- 
ture category were summarized for the 
most prevalent pathogens (those isolated 
at admission from ~5 patients in each 
treatment group). 
Approximately 198 patients were to be 
randomized to treatment to provide 148 
clinically evaluable patients, with a mini- 
mum of 74 patients in each treatment 
group. This would provide 80% power to 
test the null hypothesis, assuming an 88% 
clinical success rate in each of the treat- 
ment groups, at a significance level of 
0.025. 
RESULTS 
Between December 15,1997, and June 7, 
1999, 236 patients were randomized to 
treatment and received 1 of the 2 study 
regimens (Table I). These patients com- 
posed the intent-to-treat population. The 
levofloxacin group received IV treatment 
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Table I. Patient disposition, intent-to-treat (ITT) population (all randomized patients). 
No. (%) 
Levofloxacin Comparator Regimen* 
ITT population 115 121 
No. with completion/withdrawal information+ 110 114 
Lost to follow-up 5 I 
Total completing study 92 (83.6) 86 (75.4) 
Total withdrawals 23 (20.9) 35 (30.7) 
Reason for withdrawal 
Adverse event 5 (4.5) 5 (4.4) 
Clinical failure 4 (3.6) 6 (5.3) 
Negative radiographic findings 3 (2.7) 4 (3.5) 
Personal reason 2 (1.8) 2 (1.8) 
No study drug taken 2 (1.8) 3 (2.6) 
Other 7 (6.4) 15 (13.2) 
Modified ITT populationt 106 105 
Clinically evaluable population 85 78 
Microbiologically evaluable population 36 35 
*Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
+Percentages are based on number of patients with completion/withdrawal information. 
‘Patients in ITT population with a confirmed diagnosis of moderate to severe community-acquired pneumonia 
who took rl dose of study drug. 
for a mean of 3.67 days, and the azithro- 
mycin group received IV treatment for a 
mean of 3.83 days (plus a mean 2.36 days 
of IV ceftriaxone). Five patients in the 
levofloxacin group and 7 in the azithro- 
mycin group were lost to follow-up (eg, 
were transferred to another facility). 
Completion/withdrawal data were there- 
fore available for 110 patients in the levo- 
floxacin group and 114 in the azithromy- 
tin group. Twenty-three (20.9%) patients 
in the levofloxacin group withdrew pre- 
maturely: 5 (4.5%) due to AEs, 4 (3.6%) 
for clinical failure, 3 (2.7%) due to a neg- 
ative radiograph, and 11 (10.0%) for per- 
sonal or other reasons or because no study 
drug was taken. Thirty-five (30.7%) pa- 
tients in the azithromycin group withdrew 
prematurely: 5 (4.4%) due to AEs, 6 
(5.3%) for clinical failure, 4 (3.5%) due 
to a negative radiograph, and 20 (17.5%) 
for personal or other reasons or because 
no study drug was taken. A total of 211 
patients were included in the modified 
intent-to-treat population, 163 of whom 
were clinically evaluable and 7 1 of whom 
were microbiologically evaluable. 
Baseline demographic and disease char- 
acteristics were similar in clinically evalu- 
able patients in the 2 treatment groups 
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(Table II). The mean duration of pneumo- 
nia at baseline was 7.3 days, and the mean 
Fine risk score was 93.4. Somewhat less 
than one third (47/163) of patients were 
current smokers, with a history of 68.9 
pack years (data not shown). 
Table III lists the clinical response rates 
at the posttherapy (or early-withdrawal) 
evaluation. In clinically evaluable pa- 
tients, the clinical success rate was 94.1% 
in the levofloxacin group and 92.3% in 
the azithromycin group (95% CI, -10.20 
to 6.58). The clinical success rates in the 
modified intent-to-treat population were a 
respective 89.6% and 85.7% (95% CI, 
-13.24 to 5.43). In microbiologically 
Table II. Baseline demographic and disease characteristics of clinically evaluable 
patients .* 
Levofloxacin Comparator Regimen+ 
(n = 85) (n = 78) 
Total 
(N = 163) 
Sex, no. (%) 
Male 
Female 
Age, Y 
Mean * SD 
Range 
Race, no. (%) 
White 
Black 
Asian 
Other 
Body weight, lb 
Mean f SD 
Range 
Data missing, no. (%) 
Duration of illness, d 
Mean + SD 
Range 
Data missing, no. (%) 
Fine risk scorei 
Mean + SD 
Range 
56 (65.9) 
29 (34.1) 
67.8 f 13.11 
29-94 
68 (80.0) 
8 (9.4) 
l(l.2) 
8 (9.4) 
171.9246.85 160.6 f 41.31 
95-355 70-273 
5 (5.9) 9 (11.5) 
7.3 + 6.26 
l-32 
l(l.2) 
91.3 zt 16.93 
61-136 
60 (76.9) 
18 (23.1) 
67.3 + 13.17 
41-90 
56 (7 1.8) 
11 (14.1) 
0 (0.0) 
11 (14.1) 
7.2 f 7.23 
l-47 
I (1.3) 
95.8 + 20.24 
62-149 
116 (71.2) 
47 (28.8) 
67.6 + 13.10 
29-94 
124 (76.1) 
19 (11.7) 
1 (0.6) 
19 (11.7) 
166.7 + 44.58 
70-355 
14 (8.6) 
7.3 + 6.72 
l-47 
2 (1.2) 
93.4 f 18.67 
61-149 
*Patients with clinical signs/symptoms and a chest radiograph consistent with acute pneumonia at admission 
who had a clinical response other than unable fo evalua?e, had received consecutive doses of study drug on 
days 1 through 3 and k7 doses in the first 10 days and no concomitant or posttherapy treatment with another 
systemic antibiotic, and had a valid posttherapy evaluation. 
tcomparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
“A score of 71 to 130 is indicative of moderate to severe disease and associated need for hospitalization. 
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Table III. Clinical response rates at the end of therapy. 
Clinical Success,* no./N (%) 
Subgroup Levofloxacin Comparator Regimen+ 95% c1* 
Intent-to-treat” 100/115 (87.0) 97/121 (80.2) -16.63 to 3.04 
Modified intent-to-treat” 95/106 (89.6) 90/105 (85.7) -13.24 to 5.43 
Clinically evaluable 80/85 (94.1) 72/78 (92.3) -10.20 to 6.58 
Microbiologically evaluable 33/36 (91.7) 33/35 (94.3) -10.67 to 15.91 
*Clinical success = cure + improved. 
+Comparator egimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
*Two-sided 95% CI around the difference (comparator regimen - levofloxacin) in clinical success rates. 
“Five patients in the levofloxacin group and 10 patients in the comparator group were considered clinical suc- 
cesses based solely on the evaluation conducted during therapy. 
“Four patients in the levofloxacin group and 2 patients in the comparator group were considered clinical suc- 
cesses based solely on the evaluation conducted during therapy. 
evaluable patients, the clinical success 
rates were 91.7% and 94.3%, respectively 
(95% CI, -10.67 to 15.91). Twelve pa- 
tients in the levofloxacin group received 
only oral levofloxacin therapy. The clini- 
cal success rate in these patients was 
100%. 
Clinical and microbiologic response 
rates were comparable within each treat- 
ment group (Table IV). All 33 microbio- 
logically evaluable patients in the levo- 
floxacin group who had a posttherapy 
microbiologic response of eradicated had 
a clinical response of cure or improved. 
The 3 patients with a microbiologic re- 
sponse of persisted were classified as 
clinical failures. Of 3.5 patients in the 
azithromycin group who were micro- 
biologically evaluable and had a postther- 
apy microbiologic response of eradi- 
cated, 33 (94.3%) had a clinical response 
of cure or improved. The remaining 2 
(5.7%) patients were considered clinical 
failures. 
S pneumoniae was isolated from spu- 
tum cultures obtained from 29 patients, 
14 in the levofloxacin group and 15 in the 
azithromycin group. Haemophilus injlu- 
enzae was isolated from sputum cultures 
obtained from 22 patients, 9 in the levo- 
floxacin group and 13 in the azithromycin 
group. The eradication rate for S pneumo- 
niae in sputum cultures was 100% in both 
the levofloxacin and azithromycin groups 
(95% CI, -3.57 to 3.57); the eradication 
rate for H injkenzae was also 100% in 
both groups (95% CI, -5.56 to 5.56). 
S pneumoniae was also isolated from 
blood cultures obtained from 5 patients in 
the clinically evaluable population, 3 in 
the levofloxacin group and 2 in the azith- 
romycin group. The eradication rate for 
Spneumoniae in blood cultures was 100% 
in both the levofloxacin and azithromycin 
groups. All other pathogens isolated 
from respiratory or blood cultures oc- 
curred in <5 patients in either treatment 
group. 
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Table IV. Comparison of microbiologic and clinical response at the end of therapy. 
A. Levofloxacin (n = 36) 
Clinical Response, No. (%) 
Microbiologic response 
Eradicated* 
Persisted+ 
Total 
Cure Improved Failure Unable to Evaluate Total 
29 (87.9) 4 (12.1) 0 (0) 0 (0) 33 
0 (0) 0 (0) 3 (100) 0 (0) 3 
29 (80.6) 4 (11.1) 3 (8.3) 0 (0) 36 
B. Comparator Regimens (n = 35) 
Clinical Response, No. (%) 
Cure Improved Failure Unable to Evaluate Total 
Microbiologic response 
Eradicated* 
Persisted+ 
Total 
23 (65.7) 10 (28.6) 2 (5.7) 0 (0) 35 
0 (0) 0 (0) 0 (0) 0 (0) 0 
23 (65.7) 10 (28.6) 2 (5.7) 0 (0) 35 
*Microbiologic eradication rates are per patient (ie, they reflect eradication of all pathogens isolated at admis- 
sion from a particular patient). 
+Persisted rates include the infection categories persisted, mixed, and unable to evaluate. 
*Comparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
Table V presents the susceptibilities to tin are shown in Table VI. Of 103 isolates 
the study drugs of the 122 bacterial iso- that were susceptible to levofloxacin, 95 
lates cultured at admission. The suscepti- were also susceptible to azithromycin, 1 
bilities of 18 isolates were unknown. Of was intermediately susceptible, and 7 were 
104 admission isolates for which suscepti- resistant. The 1 isolate that was intermedi- 
bilities were determined, 103 were suscep- ately susceptible to levofloxacin was resis- 
tible to levofloxacin, 95 to azithromycin, tant to azithromycin. Table VII shows 
and 100 to ceftriaxone. One isolate was in- the cross-susceptibilities of admission 
termediately susceptible to levofloxacin, 1 pathogens to levofloxacin and ceftriaxone. 
was intermediately susceptible to azithro- Of 103 isolates that were susceptible to 
mycin, and 3 were intermediately suscep- levofloxacin, 99 were also susceptible to 
tible to ceftriaxone. None of the 104 iso- ceftriaxone, 3 were intermediately suscep- 
lates were resistant to levofloxacin, tible, and 1 was resistant. The 1 isolate that 
whereas 8 were resistant to azithromycin was intermediately susceptible to levo- 
and 1 was resistant to ceftriaxone. floxacin was susceptible to ceftriaxone. 
The cross-susceptibilities of admission 
pathogens to levofloxacin and azithromy- 
The clinical characteristics of the 5 pa- 
tients classified as treatment failures are 
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Table V. Susceptibility to study drugs of admission pathogens. 
No. of Isolates 
Levofloxacin* Azithromycin* Ceftriaxone 
Susceptible 103 9.5 100 
Intermediately susceptible 1 1 3 
Resistant 0 8 I 
Unknown 18 18 18 
Total 122 122 122 
*Two patients in the levofloxacin group and 3 patients in the comparator group were randomized to treatment 
but did not receive study medication. 
Table VI. Cross-susceptibility to levofloxacin and azithromycin of admission pathogens. 
Azithromycin,* No. of Isolates 
Intermediately 
Susceptible Susceptible Resistant Unknown Total 
Levofloxacin,” no. of isolates 
Susceptible 
Intermediately susceptible 
Resistant 
Unknown 
Total 
95 1 7 0 103 
0 0 1 0 1 
0 0 0 0 0 
0 0 0 18 18 
95 I 8 18 122 
“Two patients in the levofloxacin group and 3 patients in the comparator group were randomized to treatment 
but did not receive study medication.- 
listed in Table VIII. All patients in both 
treatment groups had significant comor- 
bidity and received study drug for s5 days. 
The 3 causative organisms in the levo- 
floxacin group were S pneumoniae (min- 
imum inhibitory concentration [MIC] 1 .O 
pg/mL) , Staphylococcus aureus (MIC 0.5 
FglmL), and H injluenzae (MIC not avail- 
able). Both organisms with documented 
MICs were susceptible to levofloxacin. 
The 2 causative organisms in the azithro- 
mycin group were H injkenzae (MIC 0.5 
pg/mL) and Escherichia coli (MIC 8.0 
Fg/mL). Because H injluenzae is consid- 
ered susceptible to azithromycin if its MIC 
is 54.0 p,g/mL and E coli is considered 
susceptible if its MIC is 52 pg/mL, the 
former was susceptible to azithromycin. 
None of the cases of pneumococcal bac- 
teremia involved a resistant organism. 
Safety Assessment 
The safety population consisted of 113 
patients in the levofloxacin group and 118 
in the azithromycin group. As seen in 
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Table VII. Cross-susceptibility to levofloxacin and ceftriaxone of admission pathogens. 
Ceftriaxone: No. of Isolates 
Intermediately 
Susceptible Susceptible Resistant Unknown Total 
Levofloxacin,* no. of isolates 
Susceptible 
Intermediately susceptible 
Resistant 
Unknown 
Total 
99 3 1 0 103 
1 0 0 0 1 
0 0 0 0 0 
0 0 0 18 18 
100 3 1 18 122 
“Two patients in the levofloxacin group and 3 patients in the comparator group were randomized to treatment 
but did not receive study medication. 
Table VIII. Clinical characteristics and minimum inhibitory concentrations (MICs) of 
pathogens identified in patients considered treatment failures. 
Treatment/Patient 
Comorbidity/ Duration of 
Adverse Event Therapy, d* Pathogen 
MIC, 
kLg/mL 
Levofloxacin 
76-year-old woman+ CHF 
39-year-old man+ Empyema 
94-year-old man+* Multiorgan failure 
Comparator regimen8 
88.year-old man Respiratory distress 
62-year-old man Left testicular 
necrosis 
3 Streptococcus pneumoniae L, 1.0 
A, 0.12 
c, so.25 
4 Staphylococcus aureus L, 0.5 
A, 1.0 
c, 2 
4 Haemophilus injluenzae NA 
3 H influenzae L, 0.5 
A, 0.5 
c, 0.25 
5 Escherichia coli L, 8.0 
A, 8.0 
C, 0.25 
CHF = congestive heart failure; L = levofloxacin; A = azithromycin; C = ceftriaxone; NA = not available. 
*Number of days before discontinuation of study drug. 
tMicrobiologically evaluable patient in whom causative pathogens were not eradicated. 
SPatient died of multiorgan failure after 6 days. 
%Jomparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
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Table IX. Drug-related adverse events. 
No. (%) 
Levofloxacin Comparator Regimen* 
(n = 113) (n = 118) 
All body systems 
Gastrointestinal disorders 
Diarrhea 
Nausea 
Pseudomembranous colitis 
Vascular disorders 
Vein disorders 
Skin and appendages 
Pruritus 
Rash 
Sweat gland disorder 
Urticaria 
Central/peripheral nervous 
system disorders 
Dizziness 
Hypoesthesia 
Psychiatric disorders 
Insomnia 
Paroniria 
Body as a whole 
6 (5.3) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
3 (2.7) 
0 (0) 
1 (0.9) 
1 (0.9) 
1 (0.9) 
1 (0.9) 
1 (0.9) 
0 (0) 
2 (1.8) 
1 (0.9) 
1 (0.9) 
1 (0.9) 
11 (9.3) 
7 (5.9) 
5 (4.2) 
1 (0.8) 
1 (0.8) 
3 (2.5) 
3 (2.5) 
2 (1.7) 
2 (1.7) 
0 (0) 
0 (0) 
0 (0) 
1 (0.8) 
0 (0) 
1 (0.8) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
*Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for 
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion. 
Table IX, the overall incidence of drug- 
related AEs for all body systems was 5.3% 
in the levofloxacin group and 9.3% in the 
azithromycin group. The most common 
drug-related AEs in the azithromycin 
group were diarrhea (4.2%), vein disor- 
ders (2.5%), and pruritus (1.7%), whereas 
no drug-related AE occurred in ~1 .O% of 
levofloxacin-treated patients. One patient 
receiving levofloxacin had a serious drug- 
related AE, compared with 7 patients re- 
ceiving azithromycin. Six deaths occurred 
during the study: 2 in the levofloxacin 
group and 4 in the azithromycin group. 
None of the deaths were considered to be 
treatment related. 
DISCUSSION 
Clinical practice guidelines are important 
tools when choosing treatment for a par- 
ticular disease state. The IDSA guidelines 
recommend doxycycline, macrolides, or 
fluoroquinolones as the preferred antimi- 
crobial agents for the empiric therapy of 
most outpatient cases of CAP, and either 
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a fluoroquinolone alone or a beta-lactam/ 
beta-lactamase inhibitor or extended- 
spectrum cephalosporin combined with a 
macrolide for most hospitalized patients 
with CAP in general medical wards.9 In 
the present trial, levofloxacin monother- 
apy was at least as effective and well tol- 
erated as traditional combination therapy 
with a macrolide and a beta-lactam in the 
treatment of moderate to severe CAP. The 
pharmacokinetics of levofloxacin are such 
that the drug achieves high concentrations 
soon after dosing that are sustained at lev- 
els far exceeding the MIC required to 
achieve 90% inhibition of most respira- 
tory pathogens in both serum and lung 
tissue.” Reports sugg est that levofloxacin 
is effective in the treatment of pneumo- 
coccal CAP (including bacteremic infec- 
tions) in patients who have failed 
macrolide therapy, as well as patients with 
bacteremic CAP.18,19 Most patients in the 
present study had significant disease, as 
indicated by a mean Fine risk score of 
93.4. They were randomized to once-daily 
treatment with levofloxacin IV or PO or 
r2 days of combination therapy with az- 
ithromycin and ceftriaxone IV, followed 
by an optional transition to azithromycin 
PO, for a total duration of treatment of 
~10 days. The addition of ceftriaxone to 
the initial azithromycin regimen was con- 
sidered a necessary safeguard in patients 
with pneumococcal bacteremia. However, 
because azithromycin was not used as 
monotherapy, this made it difficult to eval- 
uate the clinical and microbiologic out- 
come with azithromycin alone. 
The results of this trial suggest that 
levofloxacin is at least as effective as az- 
ithromycin, despite the fact that azithro- 
mycin was initially coadministered with 
ceftriaxone. Some of the inclusion and 
exclusion criteria may have limited the 
ability to extrapolate from the results. The 
clinical success rate in clinically evalu- 
able patients was 94.1% in the levofloxacin 
group and 92.3% in the azithromycin 
group. The respective microbiologic erad- 
ication rates were 89.5% and 92.3%. A 
strong correlation was observed between 
the clinical and microbiologic response in 
both treatment groups. Twelve patients in 
the levofloxacin group received oral levo- 
floxacin only, and the clinical success rate 
in this group was 100%. A total of 5 pa- 
tients were classified as treatment fail- 
ures, all of whom had received study 
drug for s5 days and all with significant 
comorbidity. 
Levofloxacin was as well tolerated as 
azithromycin, with an overall incidence 
of AEs related to all body systems of 5.3% 
and 9.3% of patients, respectively. The 
most common drug-related AEs associ- 
ated with azithromycin therapy were diar- 
rhea, vein disorders, and pruritus, whereas 
no drug-related AE occurred in >I .O% of 
levofloxacin-treated patients. Although 6 
deaths occurred during the study, none 
were considered treatment related. 
CONCLUSIONS 
Based on its clinical and microbiologic 
efficacy, as well as its favorable tolerabil- 
ity profile, levofloxacin monotherapy ap- 
pears to be effective in the management 
of hospitalized patients with moderate to 
severe CAP. 
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